JP2024516699A - Bma031抗原結合ポリペプチド - Google Patents
Bma031抗原結合ポリペプチド Download PDFInfo
- Publication number
- JP2024516699A JP2024516699A JP2023567907A JP2023567907A JP2024516699A JP 2024516699 A JP2024516699 A JP 2024516699A JP 2023567907 A JP2023567907 A JP 2023567907A JP 2023567907 A JP2023567907 A JP 2023567907A JP 2024516699 A JP2024516699 A JP 2024516699A
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- antigen
- binding polypeptide
- seq
- binding
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/428—Undefined tumor antigens, e.g. tumor lysate or antigens targeted by cells isolated from tumor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2833—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
Landscapes
- Health & Medical Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Hematology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163184698P | 2021-05-05 | 2021-05-05 | |
| EP21172352.3 | 2021-05-05 | ||
| EP21172352 | 2021-05-05 | ||
| US63/184,698 | 2021-05-05 | ||
| PCT/EP2022/062018 WO2022233957A1 (en) | 2021-05-05 | 2022-05-04 | Bma031 antigen binding polypeptides |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024516699A true JP2024516699A (ja) | 2024-04-16 |
| JP2024516699A5 JP2024516699A5 (cg-RX-API-DMAC7.html) | 2025-07-01 |
Family
ID=81579443
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023567907A Pending JP2024516699A (ja) | 2021-05-05 | 2022-05-04 | Bma031抗原結合ポリペプチド |
Country Status (14)
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201604458D0 (en) | 2016-03-16 | 2016-04-27 | Immatics Biotechnologies Gmbh | Peptides and combination of peptides for use in immunotherapy against cancers |
| DE102019121007A1 (de) | 2019-08-02 | 2021-02-04 | Immatics Biotechnologies Gmbh | Antigenbindende Proteine, die spezifisch an MAGE-A binden |
| KR20250133715A (ko) | 2023-01-06 | 2025-09-08 | 이뮤노코어 리미티드 | Prame 펩타이드-hla 복합체에 대한 결합 분자 |
| IL321809A (en) | 2023-01-06 | 2025-08-01 | Immunocore Ltd | Binding molecules against a piwil1 peptide-hla complex |
| EP4750806A1 (en) | 2023-07-27 | 2026-06-03 | Immatics Biotechnologies GmbH | Antigen binding proteins against mageb2 |
| GB202315181D0 (en) | 2023-10-03 | 2023-11-15 | Immunocore Ltd | Peptide-HLA binding molecules |
| GB202320012D0 (en) | 2023-12-22 | 2024-02-07 | Immunocore Ltd | Bispecific molecules |
| WO2025233431A1 (en) | 2024-05-07 | 2025-11-13 | Immatics Biotechnologies Gmbh | Heteromeric proteins comprising three heteromerization improving substitution, production, combinations and applications thereof |
| WO2026025031A1 (en) | 2024-07-26 | 2026-01-29 | Modernatx, Inc. | Mrna encoding mageb2 tcer molecule |
| CN119529098B (zh) * | 2025-01-22 | 2025-05-30 | 北京可瑞生物科技有限公司 | 对mage-a1具有特异性的结合分子和抗cd3的融合蛋白 |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020236795A2 (en) * | 2019-05-21 | 2020-11-26 | Novartis Ag | Trispecific binding molecules against bcma and uses thereof |
| WO2021023658A1 (en) * | 2019-08-02 | 2021-02-11 | Immatics Biotechnologies Gmbh | Antigen binding proteins specifically binding mage-a |
| WO2021023657A1 (en) * | 2019-08-02 | 2021-02-11 | Immatics Biotechnologies Gmbh | Modified bi specific anti cd3 antibodies |
| WO2021073624A1 (zh) * | 2019-10-17 | 2021-04-22 | 北京门罗生物科技有限公司 | 用于免疫治疗的嵌合抗原受体、制备方法及其应用 |
Family Cites Families (197)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2018248A1 (en) | 1989-06-07 | 1990-12-07 | Clyde W. Shearman | Monoclonal antibodies against the human alpha/beta t-cell receptor, their production and use |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| EP1124568B1 (en) | 1998-10-21 | 2007-08-22 | Altor BioScience Corporation | Polyspecific binding molecules and uses thereof |
| EP2322228B1 (en) | 2000-06-05 | 2018-01-10 | Altor BioScience Corporation | T cell receptor fusion proteins and conjugates and methods of use thereof |
| EP1809669A2 (en) | 2004-10-01 | 2007-07-25 | Avidex Ltd | T-cell receptors containing a non-native disulfide interchain bond linked to therapeutic agents |
| US7649083B2 (en) | 2006-06-02 | 2010-01-19 | Aveo Pharmaceuticals, Inc. | Hepatocyte growth factor (HGF) binding antibody |
| CA2735193A1 (en) | 2008-08-26 | 2010-03-11 | Macrogenics, Inc. | T-cell receptor antibodies and methods of use thereof |
| GB0908613D0 (en) | 2009-05-20 | 2009-06-24 | Immunocore Ltd | T Cell Reseptors |
| GB201004551D0 (en) | 2010-03-19 | 2010-05-05 | Immatics Biotechnologies Gmbh | NOvel immunotherapy against several tumors including gastrointestinal and gastric cancer |
| CN101928347B (zh) | 2010-05-05 | 2013-03-27 | 上海海抗中医药科技发展有限公司 | 抗癌胚抗原抗体及其应用 |
| TWI736437B (zh) | 2010-11-30 | 2021-08-11 | 日商中外製藥股份有限公司 | 細胞傷害誘導治療劑 |
| UY34317A (es) | 2011-09-12 | 2013-02-28 | Genzyme Corp | Anticuerpo antireceptor de célula T (alfa)/ß |
| WO2013048243A1 (en) | 2011-09-29 | 2013-04-04 | Apo-T B.V. | Multi-specific binding molecules targeting aberrant cells |
| KR20150029714A (ko) | 2012-07-13 | 2015-03-18 | 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 | 이중특이적 항체의 공-도입에 의한 car 세포의 활성 증강 |
| US9790268B2 (en) | 2012-09-12 | 2017-10-17 | Genzyme Corporation | Fc containing polypeptides with altered glycosylation and reduced effector function |
| US9580511B2 (en) | 2013-03-11 | 2017-02-28 | Genzyme Corporation | Site-specific antibody-drug conjugation through glycoengineering |
| US20140308285A1 (en) | 2013-03-15 | 2014-10-16 | Amgen Inc. | Heterodimeric bispecific antibodies |
| EP3027204B1 (en) | 2013-07-29 | 2022-01-05 | 2seventy bio, Inc. | Multipartite signaling proteins and uses thereof |
| CN106795220A (zh) | 2013-10-30 | 2017-05-31 | 建新公司 | 通过αβTCR结合多肽的多重施用的用于增强免疫抑制疗法的方法 |
| EP3220928B1 (en) | 2014-11-20 | 2022-10-05 | UMC Utrecht Holding B.V. | A method of obtaining a preparation enrichmed in engineered t cells with exogenous immune receptors |
| GB201423361D0 (en) | 2014-12-30 | 2015-02-11 | Immatics Biotechnologies Gmbh | Method for the absolute Quantification of naturally processed HLA-Restricted cancer peptides |
| GB201504502D0 (en) | 2015-03-17 | 2015-04-29 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against pancreatic cancer and other cancers |
| GB201505305D0 (en) | 2015-03-27 | 2015-05-13 | Immatics Biotechnologies Gmbh | Novel Peptides and combination of peptides for use in immunotherapy against various tumors |
| GB201505585D0 (en) | 2015-03-31 | 2015-05-13 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides and scaffolds for use in immunotherapy against renal cell carinoma (RCC) and other cancers |
| GB201507719D0 (en) | 2015-05-06 | 2015-06-17 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides and scaffolds thereof for use in immunotherapy against colorectal carcinoma (CRC) and other cancers |
| HRP20191800T1 (hr) | 2015-05-13 | 2019-12-27 | Ablynx N.V. | Polipeptidi koji regrutiraju t stanice koji se temelje na tcr alfa/beta reaktivnosti |
| ES2984656T3 (es) | 2015-05-13 | 2024-10-30 | Ablynx Nv | Polipéptidos que reclutan linfocitos T en función de la reactividad a CD3 |
| GB201510771D0 (en) | 2015-06-19 | 2015-08-05 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy and methods for generating scaffolds for the use against pancreatic cancer |
| GB201511191D0 (en) | 2015-06-25 | 2015-08-12 | Immatics Biotechnologies Gmbh | T-cell epitopes for the immunotherapy of myeloma |
| GB201511546D0 (en) | 2015-07-01 | 2015-08-12 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers |
| GB201511792D0 (en) | 2015-07-06 | 2015-08-19 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against esopageal cancer and other cancers |
| GB201512369D0 (en) | 2015-07-15 | 2015-08-19 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against epithelial ovarian cancer and other cancers |
| GB201513921D0 (en) | 2015-08-05 | 2015-09-23 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers |
| US10159726B2 (en) | 2015-08-28 | 2018-12-25 | Immatics Biotechnologies Gmbh | Peptides, combination of peptides and scaffolds for use in immunotherapeutic treatment of various cancers |
| GB201517538D0 (en) | 2015-10-05 | 2015-11-18 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against small cell lung cancer and other cancers |
| WO2017060201A1 (en) | 2015-10-09 | 2017-04-13 | Immatics Biotechnologies Gmbh | Anti-wt1/hla-specific antibodies |
| MX2018004721A (es) | 2015-10-23 | 2018-07-06 | Eureka Therapeutics Inc | Construcciones quimericas anticuerpo/receptor de celulas t y usos de las mismas. |
| GB201604468D0 (en) | 2016-03-16 | 2016-04-27 | Immunocore Ltd & Adaptimmune Ltd | Peptides |
| GB201520595D0 (en) | 2015-11-23 | 2016-01-06 | Immunocore Ltd & Adaptimmune Ltd | Peptides |
| GB201520539D0 (en) | 2015-11-23 | 2016-01-06 | Immunocore Ltd & Adaptimmune Ltd | Peptides |
| GB201520589D0 (en) | 2015-11-23 | 2016-01-06 | Immunocore Ltd & Adaptimmune Ltd | Peptides |
| GB201520564D0 (en) | 2015-11-23 | 2016-01-06 | Immunocore Ltd & Adaptimmune Ltd | Peptides |
| GB201520559D0 (en) | 2015-11-23 | 2016-01-06 | Immunocore Ltd & Adaptimmune Ltd | Peptides |
| GB201521746D0 (en) | 2015-12-10 | 2016-01-27 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against CLL and other cancers |
| GB201521894D0 (en) | 2015-12-11 | 2016-01-27 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against various cancers |
| GB201522667D0 (en) | 2015-12-22 | 2016-02-03 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against breast cancer and other cancers |
| GB201602918D0 (en) | 2016-02-19 | 2016-04-06 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against NHL and other cancers |
| GB201603568D0 (en) | 2016-03-01 | 2016-04-13 | Immatics Biotechnologies Gmbh | Efficient treatment options including peptides and combination of peptide and cell based medicaments for use in immunotherapy against urinary bladder cancer |
| GB201603987D0 (en) | 2016-03-08 | 2016-04-20 | Immatics Biotechnologies Gmbh | Uterine cancer treatments |
| GB201604494D0 (en) | 2016-03-16 | 2016-04-27 | Immatics Biotechnologies Gmbh | Transfected T-Cells and T-Cell receptors for use in immunotherapy against cancers |
| GB201604492D0 (en) | 2016-03-16 | 2016-04-27 | Immatics Biotechnologies Gmbh | Transfected t-cells and t-cell receptors for use in immunotherapy against cancers |
| GB201604458D0 (en) | 2016-03-16 | 2016-04-27 | Immatics Biotechnologies Gmbh | Peptides and combination of peptides for use in immunotherapy against cancers |
| WO2017167350A1 (en) | 2016-03-30 | 2017-10-05 | Horst Lindhofer | Multispecific antibodies for use in the treatment of a neoplasm of the urinary tract |
| DE102016115246C5 (de) | 2016-08-17 | 2018-12-20 | Immatics Biotechnologies Gmbh | Neue t-zellrezeptoren und deren verwendung in immuntherapie |
| ZA201900664B (en) | 2016-08-17 | 2021-09-29 | Paul Ehrlich Strasse 15 Tuebingen 72076 Germany | T cell receptors and immune therapy using the same |
| EP3300863B1 (en) | 2016-09-28 | 2020-06-17 | Braun GmbH | Electric shaver |
| US11840569B2 (en) | 2016-11-16 | 2023-12-12 | Ablynx N.V. | T cell recruiting polypeptides capable of binding CD123 and TCR alpha/beta |
| WO2018094414A1 (en) | 2016-11-21 | 2018-05-24 | Obi Pharma, Inc. | Conjugated biological molecules, pharmaceutical compositions and methods |
| WO2018099539A1 (en) | 2016-11-29 | 2018-06-07 | Horst Lindhofer | Combination of t-cell redirecting multifunctional antibodies with immune checkpoint modulators and uses thereof |
| DE102016123859B3 (de) | 2016-12-08 | 2018-03-01 | Immatics Biotechnologies Gmbh | Neue T-Zellrezeptoren und deren Verwendung in Immuntherapie |
| DE102016123847B3 (de) | 2016-12-08 | 2018-04-05 | Immatics Biotechnologies Gmbh | Neue T-Zellrezeptoren und deren Verwendung in Immuntherapie |
| DE102017106305A1 (de) | 2017-03-23 | 2018-09-27 | Immatics Biotechnologies Gmbh | Neue T-Zellrezeptoren und deren Verwendung in Immuntherapien gegen prame-positive Krebsarten |
| TW201841934A (zh) | 2017-04-10 | 2018-12-01 | 德商英麥提克生物技術股份有限公司 | 用於治療癌症免疫治療的新穎肽及其肽組合物 |
| TW201841937A (zh) | 2017-04-10 | 2018-12-01 | 德商英麥提克生物技術股份有限公司 | 用於白血病和其他癌症免疫治療的新穎肽和肽組合物 |
| DE102017114737A1 (de) | 2017-06-30 | 2019-01-03 | Immatics Biotechnologies Gmbh | Neue T-Zellrezeptoren und deren Verwendung in Immuntherapie |
| WO2019033050A1 (en) | 2017-08-11 | 2019-02-14 | City Of Hope | BISPECIFIC MOLECULE FOR BINDING TO ANTIGEN |
| AU2018314236B2 (en) | 2017-08-11 | 2025-02-06 | Apterna Limited | RNA aptamers against transferrin receptor (TfR) |
| WO2019129850A1 (en) | 2017-12-29 | 2019-07-04 | Cellectis | Off-the-shelf engineered cells for therapy |
| DE102018100967B4 (de) | 2018-01-17 | 2019-08-14 | Immatics US, Inc. | Verfahren zur feststellung der wirksamkeit von viralen vektoren |
| JPWO2019151392A1 (ja) | 2018-01-31 | 2021-02-04 | 国立大学法人東北大学 | 抗原特異的mhc発現調節法 |
| KR20200119840A (ko) | 2018-02-09 | 2020-10-20 | 이매틱스 유에스 인코포레이티드 | T 세포의 제조 방법 |
| DE102018107224A1 (de) | 2018-02-21 | 2019-08-22 | Immatics Biotechnologies Gmbh | Peptide und Kombinationen von Peptiden nicht-kanonischen Ursprungs zur Verwendung in der Immuntherapie gegen verschiedene Krebsarten |
| DE102018108612A1 (de) | 2018-03-21 | 2019-09-26 | Immatics US, Inc. | Verfahren zur erhöhung der persistenz von adoptiv infundierten t-zellen |
| CN112469440B (zh) | 2018-06-18 | 2024-09-06 | 优瑞科生物技术公司 | 靶向前列腺特异性膜抗原(psma)的构建体和其用途 |
| US12162947B2 (en) | 2018-09-04 | 2024-12-10 | Nanjing Umab-Biopharma Co., Ltd. | Fusion protein and its applicaton in preparing medicine for treating tumor and/or viral infection |
| EP3890773A4 (en) | 2018-11-08 | 2022-11-09 | Orionis Biosciences, Inc. | MODULATION OF DENDRITIC CELL LINES |
| JP7700039B2 (ja) | 2019-01-04 | 2025-06-30 | マレンゴ・セラピューティクス,インコーポレーテッド | 抗tcr抗体分子およびその使用 |
| WO2020150364A1 (en) | 2019-01-15 | 2020-07-23 | Altor Bioscience, Llc | Human immunodeficiency virus-specific t cell receptors |
| LT4279082T (lt) | 2019-01-17 | 2026-05-11 | Immunocore Limited | Farmacinės kompozicijos |
| GB201901306D0 (en) | 2019-01-30 | 2019-03-20 | Immunocore Ltd | Multi-domain binding molecules |
| GB201901305D0 (en) | 2019-01-30 | 2019-03-20 | Immunocore Ltd | Specific binding molecules |
| BR112021015009A2 (pt) | 2019-02-15 | 2021-10-05 | Allakos Inc. | Métodos e composições para o tratamento da gastrite mastocística, esofagite mastocística, enterite mastocística, duodenite mastocística e/ou gastroenterite mastocística |
| US12473346B2 (en) | 2019-03-18 | 2025-11-18 | Ludwig Institute For Cancer Research Ltd | A2/NY-ESO-1 specific t cell receptors and uses thereof |
| GB201904328D0 (en) | 2019-03-28 | 2019-05-15 | Immunocore Ltd | Specific binding molecules |
| UY38701A (es) | 2019-05-21 | 2020-12-31 | Novartis Ag | Moléculas de unión a cd19, conjugados, composiciones que las comprenden y usos de las mismas |
| KR20220012313A (ko) | 2019-05-23 | 2022-02-03 | 벨로스바이오 인코포레이티드 | 항-ror1/항-cd3 이중특이적 결합 분자 |
| WO2020238926A1 (en) | 2019-05-28 | 2020-12-03 | Single Cell Technology, Inc. | Anti-b7-h3 antibodies |
| TWI844684B (zh) | 2019-06-04 | 2024-06-11 | 大陸商普米斯生物技術(珠海)有限公司 | 一種抗ceacam5的單殖株抗體及其製備方法和用途 |
| EP3980129A1 (en) | 2019-06-07 | 2022-04-13 | Mythic Therapeutics, Inc. | Antigen-binding protein constructs and uses thereof |
| CA3141914A1 (en) | 2019-06-07 | 2020-12-10 | Adimab, Llc | Engineered ph-dependent anti-cd3 antibodies, and methods for their generation and use |
| MX2021015533A (es) | 2019-06-19 | 2022-02-10 | Silverback Therapeutics Inc | Anticuerpos anti-mesotelina e inmunoconjugados de los mismos. |
| MX2022001403A (es) | 2019-08-02 | 2022-03-25 | Allakos Inc | Metodos de administracion de anticuerpos anti-siglec-8 y corticosteroides. |
| EP3907240A4 (en) | 2019-08-02 | 2023-02-22 | Jiangsu Simcere Pharmaceutical Co., Ltd. | ANTI-TNFR2 ANTIBODIES AND USE THEREOF |
| CN112390892B (zh) | 2019-08-14 | 2024-01-12 | 博源润生医药(杭州)有限公司 | 一种嵌合抗原受体以及表达该嵌抗原受体的免疫效应细胞 |
| CN111454357B (zh) | 2019-08-14 | 2022-03-15 | 康诺亚生物医药科技(成都)有限公司 | 一种含有抗体的肿瘤治疗剂的开发和应用 |
| JP2022544543A (ja) | 2019-08-15 | 2022-10-19 | シルバーバック セラピューティックス インコーポレイテッド | ベンザゼピンコンジュゲートの製剤およびその使用 |
| KR20220050971A (ko) | 2019-08-27 | 2022-04-25 | 엘피사이언스 (쑤저우) 바이오파마, 엘티디. | 신규 항-cd39 항체 |
| GB201912681D0 (en) | 2019-09-04 | 2019-10-16 | Eth Zuerich | Bispecific binding agent that binds to cd117/c-kit and cd3 |
| WO2021043961A1 (en) | 2019-09-06 | 2021-03-11 | Glaxosmithkline Intellectual Property Development Limited | Dosing regimen for the treatment of cancer with an anti icos agonistic antibody and chemotherapy |
| WO2021046293A1 (en) | 2019-09-06 | 2021-03-11 | Glaxosmithkline Intellectual Property Development Limited | Dosing regimen for the treatment of cancer with an anti icos agonistic antibody and tremelimumab |
| KR20220088428A (ko) | 2019-09-26 | 2022-06-27 | 주식회사 에스티큐브앤컴퍼니 | 글리코실화된 ctla-4에 대해 특이적인 항체 및 이의 사용 방법 |
| US10975169B1 (en) | 2019-09-27 | 2021-04-13 | Memorial Sloan Kettering Cancer Center | Methods for treating diabetic retinopathy using anti-ceramide monoclonal antibody 2A2 |
| AU2020358898B2 (en) | 2019-10-01 | 2025-10-16 | Epsilogen Ltd | Hybrid antibody |
| CN114828861A (zh) | 2019-10-10 | 2022-07-29 | 亚利桑那州立大学董事会 | 表达多特异性免疫细胞接合器的溶瘤病毒 |
| BR112022007128A2 (pt) | 2019-10-15 | 2022-07-05 | Dragonfly Therapeutics Inc | Ligação de proteínas nkg2d, cd16 e flt3 |
| CN115348972A (zh) | 2019-10-15 | 2022-11-15 | 蜻蜓疗法股份有限公司 | 靶向flt3的抗体及其用途 |
| JP7450710B2 (ja) | 2019-10-21 | 2024-03-15 | 上▲海▼宏成▲薬▼▲業▼有限公司 | 抗pd-l1抗体及びその製薬用途 |
| GB201915282D0 (en) | 2019-10-22 | 2019-12-04 | Immunocore Ltd | Specific binding molecules |
| EP4048701A4 (en) | 2019-10-23 | 2024-05-29 | Lyvgen Biopharma Holdings Limited | Anti-cd40 binding molecules and bi-specific antibodies comprising such |
| EP4051712A4 (en) | 2019-11-01 | 2023-11-29 | Merck Sharp & Dohme LLC | Dosing regimen of anti-cd27 antibodies for treatment of cancer |
| CN115038718B (zh) | 2019-11-08 | 2024-07-02 | 山东先声生物制药有限公司 | 抗人程序性死亡配体-1(pd-l1)的抗体及其用途 |
| US20220380720A1 (en) | 2019-11-12 | 2022-12-01 | Actym Therapeutics, Inc. | Immunostimulatory bacteria delivery platforms and their use for delivery of therapeutic products |
| EP3822288A1 (en) | 2019-11-18 | 2021-05-19 | Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts | Antibodies targeting, and other modulators of, the cd276 antigen, and uses thereof |
| KR20220115572A (ko) | 2019-11-18 | 2022-08-17 | 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 | 항-b7-h3 단클론성 항체 및 이의 사용 방법 |
| IL293108A (en) | 2019-11-19 | 2022-07-01 | Univ Pennsylvania | Monoclonal antibodies against alpha-synuclein, and methods of using them |
| NL2024375B1 (en) | 2019-12-04 | 2021-08-31 | Apo T B V | Methods and means for attracting immune effector cells to tumor cells. |
| MX2022006676A (es) | 2019-12-04 | 2022-07-05 | Ac Immune Sa | Nuevas moleculas para terapia y diagnostico. |
| WO2021113831A1 (en) | 2019-12-05 | 2021-06-10 | Compugen Ltd. | Anti-pvrig and anti-tigit antibodies for enhanced nk-cell based tumor killing |
| EP4069735A1 (en) | 2019-12-06 | 2022-10-12 | OncoOne Research & Development GmbH | Anti-oxmif/anti-cd3 bispecific antibody constructs |
| CN115916818A (zh) | 2019-12-11 | 2023-04-04 | 库利南肿瘤股份有限公司 | 抗cd19抗体和多特异性结合蛋白 |
| CN115515678A (zh) | 2019-12-23 | 2022-12-23 | 基因泰克公司 | 载脂蛋白l1特异性抗体及其使用方法 |
| US20230054266A1 (en) | 2019-12-30 | 2023-02-23 | Edigene Biotechnology Inc. | Method for purifying ucart cell and use thereof |
| EP4086340A1 (en) | 2019-12-30 | 2022-11-09 | Edigene Biotechnology Inc. | Universal car-t targeting t-cell lymphoma cell and preparation method therefor and use thereof |
| CN113088495B (zh) | 2020-01-09 | 2024-08-16 | 苏州方德门达新药开发有限公司 | 工程改造的t细胞、其制备及应用 |
| US20230338421A1 (en) | 2020-01-10 | 2023-10-26 | TCR2 Therapeutics Inc. | Compositions and methods for autoimmunity regulation |
| CN119930824A (zh) | 2020-01-13 | 2025-05-06 | 真和制药有限公司 | 抗Gal3抗体和使用方法 |
| CN115768483A (zh) | 2020-01-13 | 2023-03-07 | 西纳福克斯股份有限公司 | 抗体与免疫细胞衔接器的缀合物 |
| CN113214395A (zh) | 2020-01-21 | 2021-08-06 | 迈威(上海)生物科技股份有限公司 | 抗st2抗体及其应用 |
| US12692311B2 (en) | 2020-01-29 | 2026-07-28 | William Robert Arathoon Living Trust Dated August 29, 2016 | Anti-MDR1 antibodies and uses thereof |
| US11976133B2 (en) | 2020-01-31 | 2024-05-07 | Gensun Biopharma Inc. | Bispecific T cell engagers |
| BR102020002165A2 (pt) | 2020-01-31 | 2021-11-30 | Fundação Oswaldo Cruz | Anticorpo, seu uso, composição farmacêutica o compreendendo, método de diagnóstico de infecções fúngicas, kit de diagnóstico de infecções fúngicas e método para tratamento de infecções fúngicas. |
| EP4103618A4 (en) | 2020-02-12 | 2024-05-01 | The Scripps Research Institute | LONG-ACTING GM-CSF AND METHODS OF USE |
| BR112022015982A2 (pt) | 2020-02-12 | 2022-10-11 | Abbvie Inc | Moléculas de ligação bispecíficas |
| AU2021227406A1 (en) | 2020-02-24 | 2022-09-29 | Oblique Therapeutics Ab | Kras epitopes and antibodies |
| CN115279412A (zh) | 2020-02-27 | 2022-11-01 | 凡恩世制药公司 | 偶联脂肪酸分子的抗体及其用途 |
| JP2023516008A (ja) | 2020-02-27 | 2023-04-17 | ノバルティス アーゲー | キメラ抗原受容体発現細胞を作製する方法 |
| US20240067738A1 (en) | 2020-03-18 | 2024-02-29 | Elanco Us Inc. | Anti-il4 receptor antibodies for veterinary use |
| MX2022011958A (es) | 2020-03-27 | 2023-01-11 | Angiex Inc | Conjugados de anticuerpo degradador y métodos de uso de los mismos. |
| WO2021202590A1 (en) | 2020-03-31 | 2021-10-07 | Alector Llc | Anti-mertk antibodies and methods of use thereof |
| EP4132578A1 (en) | 2020-04-06 | 2023-02-15 | Universität Zürich | Artc1 ligands for cancer treatment |
| GB202005216D0 (en) | 2020-04-08 | 2020-05-20 | Autolus Ltd | Cell |
| JP2023521228A (ja) | 2020-04-14 | 2023-05-23 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド | 癌の併用療法 |
| AU2021256925A1 (en) | 2020-04-14 | 2022-11-03 | Ares Trading S.A. | Combination treatment for cancer based upon an ICOS antibody and a PD-L1 antibody TGF-beta-receptor fusion protein |
| WO2021209356A1 (en) | 2020-04-14 | 2021-10-21 | Glaxosmithkline Intellectual Property Development Limited | Combination treatment for cancer |
| CN116096413A (zh) | 2020-04-22 | 2023-05-09 | 伊穆奈克斯特股份有限公司 | 抗人vista抗体及其用途 |
| JP2023524102A (ja) | 2020-04-30 | 2023-06-08 | ザ チルドレンズ メディカル センター コーポレーション | Abcb5に特異的な抗体およびその使用 |
| WO2021222783A1 (en) | 2020-05-01 | 2021-11-04 | Angiex, Inc. | Anti-tm4sf1 antibody drug conjugates and methods of using same |
| CN116096754A (zh) | 2020-05-04 | 2023-05-09 | 免疫里森公司 | 前体三特异性抗体构建体及其使用方法 |
| GB202006629D0 (en) | 2020-05-05 | 2020-06-17 | Immunocore Ltd | Specific binding molecules |
| CN121914272A (zh) | 2020-05-12 | 2026-04-24 | 正大天晴药业集团股份有限公司 | St2抗原结合蛋白 |
| MX2022014786A (es) | 2020-05-26 | 2023-01-16 | Truebinding Inc | Metodos para tratar enfermedades inflamatorias mediante el bloqueo de galectina-3. |
| CA3181776A1 (en) | 2020-05-26 | 2021-12-02 | Boehringer Ingelheim International Gmbh | Anti-pd-1 antibodies |
| WO2021237717A1 (zh) | 2020-05-29 | 2021-12-02 | 武汉友芝友生物制药有限公司 | 抗cldn18.2和cd3的双特异性抗体 |
| CN113754766A (zh) | 2020-06-02 | 2021-12-07 | 明慧医药(上海)有限公司 | 抗b7-h3抗体及其制备和应用 |
| KR20230021018A (ko) | 2020-06-05 | 2023-02-13 | 재단법인 생물기술개발중심 | 항-메조텔린 항체를 함유하는 항체-약물 컨쥬게이트 및 이의 용도 |
| GB202008860D0 (en) | 2020-06-11 | 2020-07-29 | Univ Oxford Innovation Ltd | BTLA antibodies |
| IL299339A (en) | 2020-06-23 | 2023-02-01 | Antengene Biologics Ltd | Antibodies and methods for treating claudin-related diseases |
| EP3932944A1 (en) | 2020-06-29 | 2022-01-05 | GlaxoSmithKline Biologicals S.A. | Hsv ge antibodies |
| EP4172195A1 (en) | 2020-06-29 | 2023-05-03 | GlaxoSmithKline Biologicals S.A. | Hsv gegi heterodimer antibodies |
| CN111662384B (zh) | 2020-06-30 | 2021-04-09 | 广州百暨基因科技有限公司 | 抗b7h3抗体及其应用 |
| BR112022026533A2 (pt) | 2020-07-02 | 2023-01-17 | Beijing Tuo Jie Biopharmaceutical Co Ltd | Anticorpo anti-fxi/fxia, fragmento de ligação do mesmo, e antígenos e uso farmacêutico do mesmo |
| WO2022005678A1 (en) | 2020-07-02 | 2022-01-06 | H. Lee Moffitt Cancer Center And Research Institute Inc. | Dual chimeric antigen receptor t cells targeting ccd99- and clec12a-expressing cancers |
| GB202010329D0 (en) | 2020-07-06 | 2020-08-19 | Immunocore Ltd | Specific binding molecules |
| EP4188449A4 (en) | 2020-07-31 | 2025-12-17 | Angiex Inc | ANTI-TM4SF1 ANTIBODY AGENT CONJUGATES WITH CRISPABLE LINKERS AND METHOD FOR USE THEREMISH |
| JP2023536935A (ja) | 2020-08-07 | 2023-08-30 | ノヴェルジェン カンパニー リミテッド | コロナウイルスに対する抗ウイルス用組成物 |
| KR102799318B1 (ko) | 2020-08-11 | 2025-04-23 | 주식회사 카나프테라퓨틱스 | Il-12 및 항-fap 항체를 포함하는 융합단백질 및 이의 용도 |
| US20220119824A1 (en) | 2020-08-12 | 2022-04-21 | Actym Therapeutics, Inc. | Immunostimulatory bacteria-based vaccines, therapeutics, and rna delivery platforms |
| US11919958B2 (en) | 2020-08-19 | 2024-03-05 | Xencor, Inc. | Anti-CD28 compositions |
| WO2022040454A1 (en) | 2020-08-20 | 2022-02-24 | A2 Biotherapeutics, Inc. | Compositions and methods for treating mesothelin positive cancers |
| EP3957308A1 (en) | 2020-08-21 | 2022-02-23 | Palobiofarma, S.L. | (1r,3s)-3-((5-cyano-4-phenylthiazol-2-yl)carbamoyl)cyclopentane-1-carboxylic acid and derivatives thereof for use in the treatment of airway diseases |
| US12037409B2 (en) | 2020-08-21 | 2024-07-16 | Shanghai GenBase Biotechnology Co., Ltd. | Antibody specifically bound to glycosylated CEACAM5 |
| JP7748105B2 (ja) | 2020-08-25 | 2025-10-02 | 学校法人 久留米大学 | ウイルス感染の判定方法 |
| AU2021331075A1 (en) | 2020-08-26 | 2023-04-06 | Marengo Therapeutics, Inc. | Multifunctional molecules that bind to calreticulin and uses thereof |
| WO2022046941A1 (en) | 2020-08-26 | 2022-03-03 | Angiex, Inc. | Antimitotic tetrapeptide-antibody conjugates and methods of using same |
| WO2022045247A1 (ja) | 2020-08-27 | 2022-03-03 | 学校法人順天堂 | 抗切断型変異calr-cd3二重特異性抗体及び医薬組成物 |
| JP2023540373A (ja) | 2020-09-08 | 2023-09-22 | ノヴェルジェン カンパニー リミテッド | インフルエンザaウイルスに対する抗ウイルス用組成物 |
| US20230355764A1 (en) | 2020-09-13 | 2023-11-09 | Shandong Boan Biotechnology Co., Ltd. | Downregulation of membrane-bound proteins by receptor tac technology |
| WO2022061032A1 (en) | 2020-09-17 | 2022-03-24 | Allakos Inc. | Methods and compositions for treating viral infection |
| WO2022057941A1 (zh) | 2020-09-21 | 2022-03-24 | 克莱格医学有限公司 | 表达il-7r结合蛋白的免疫效应细胞 |
| WO2022063272A1 (en) | 2020-09-28 | 2022-03-31 | Elpiscience (Suzhou) Biopharma, Ltd. | Novel anti-claudin18 antibodies |
| CA3196055A1 (en) | 2020-09-28 | 2022-03-31 | Navrogen, Inc. | Composition and use of alternatively formatted anti-mesothelin antibodies for the treatment of cancer |
| CN116419971A (zh) | 2020-09-30 | 2023-07-11 | 南京金斯瑞生物科技有限公司 | 抗SARS-CoV-2刺突蛋白膜外区的单克隆抗体及其应用 |
| WO2022072538A1 (en) | 2020-09-30 | 2022-04-07 | Biotheryx, Inc. | Antibody-drug conjugates, pharmaceutical compositions thereof, and their therapeutic applications |
| WO2022082068A1 (en) | 2020-10-18 | 2022-04-21 | Ardeagen Corporation | Anti-msln binding agents, conjugates thereof and methods of using the same |
| AU2021365008A1 (en) | 2020-10-22 | 2023-06-08 | Allakos Inc. | Anti-siglec-8 antibody formulations |
| WO2022094174A1 (en) | 2020-10-30 | 2022-05-05 | Children's Hospital Medical Center | Compositions and methods for the treatment of esophageal conditions |
| US12116411B2 (en) | 2020-11-03 | 2024-10-15 | Abzyme Therapeutics Llc | Antibodies binding to human CD3 at acidic pH |
| US20240010747A1 (en) | 2020-11-13 | 2024-01-11 | Kenjockety Biotechnology, Inc. | Anti-mrp4 (encoded by abcc4 gene) antibodies and uses thereof |
| EP4251650A4 (en) | 2020-11-27 | 2024-10-23 | Elpiscience (Suzhou) Biopharma, Ltd. | Novel conjugate molecules targeting cd39 and tgfbeta |
| CN116964090A (zh) | 2020-12-14 | 2023-10-27 | 武田药品工业有限公司 | 条件性双特异性结合蛋白 |
| CN114634566B (zh) | 2020-12-16 | 2023-09-19 | 广州百暨基因科技有限公司 | 一种抗Claudin18_2的抗原结合片段、抗体及其应用 |
| US20240317871A1 (en) | 2020-12-30 | 2024-09-26 | Immunomic Therapeutics, Inc. | Anti-HVEM Antibodies |
| WO2022148736A1 (en) | 2021-01-05 | 2022-07-14 | Transgene | Vectorization of muc1 t cell engager |
| EP4271387A4 (en) | 2021-01-07 | 2026-01-28 | Immunext Inc | NEW STEROID PAYLOAD, STEROID BINDERS, CONTAINERS AND ASSOCIATED USES |
| EP4032910A1 (en) | 2021-01-22 | 2022-07-27 | ETH Zurich | Bispecific binding agent that binds to cd3 and a fluorophore |
| JP2024506022A (ja) | 2021-02-08 | 2024-02-08 | シンアフィックス ビー.ブイ. | 多機能性抗体 |
| IL305175A (en) | 2021-02-19 | 2023-10-01 | Angeles Therapeutics Inc | Single-chain and multi-chain synthetic antigen receptors for diverse immune cells |
-
2022
- 2022-05-04 KR KR1020237041783A patent/KR20240004937A/ko active Pending
- 2022-05-04 BR BR112023022975A patent/BR112023022975A2/pt not_active Application Discontinuation
- 2022-05-04 IL IL308258A patent/IL308258A/en unknown
- 2022-05-04 TW TW111116826A patent/TW202309090A/zh unknown
- 2022-05-04 JP JP2023567907A patent/JP2024516699A/ja active Pending
- 2022-05-04 CA CA3217739A patent/CA3217739A1/en active Pending
- 2022-05-04 PE PE2023002995A patent/PE20242345A1/es unknown
- 2022-05-04 WO PCT/EP2022/062018 patent/WO2022233957A1/en not_active Ceased
- 2022-05-04 MX MX2023012899A patent/MX2023012899A/es unknown
- 2022-05-04 EP EP22720738.8A patent/EP4334350A1/en active Pending
- 2022-05-04 US US17/736,699 patent/US12162940B2/en active Active
- 2022-05-04 AU AU2022269828A patent/AU2022269828A1/en not_active Abandoned
-
2023
- 2023-10-26 CL CL2023003218A patent/CL2023003218A1/es unknown
- 2023-10-30 CO CONC2023/0014734A patent/CO2023014734A2/es unknown
-
2024
- 2024-10-29 US US18/929,969 patent/US20250051445A1/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020236795A2 (en) * | 2019-05-21 | 2020-11-26 | Novartis Ag | Trispecific binding molecules against bcma and uses thereof |
| WO2021023658A1 (en) * | 2019-08-02 | 2021-02-11 | Immatics Biotechnologies Gmbh | Antigen binding proteins specifically binding mage-a |
| WO2021023657A1 (en) * | 2019-08-02 | 2021-02-11 | Immatics Biotechnologies Gmbh | Modified bi specific anti cd3 antibodies |
| WO2021073624A1 (zh) * | 2019-10-17 | 2021-04-22 | 北京门罗生物科技有限公司 | 用于免疫治疗的嵌合抗原受体、制备方法及其应用 |
Also Published As
| Publication number | Publication date |
|---|---|
| PE20242345A1 (es) | 2024-12-16 |
| US12162940B2 (en) | 2024-12-10 |
| WO2022233957A1 (en) | 2022-11-10 |
| MX2023012899A (es) | 2023-11-08 |
| CA3217739A1 (en) | 2022-11-10 |
| AU2022269828A1 (en) | 2023-11-23 |
| CL2023003218A1 (es) | 2024-04-19 |
| TW202309090A (zh) | 2023-03-01 |
| US20220356252A1 (en) | 2022-11-10 |
| US20250051445A1 (en) | 2025-02-13 |
| EP4334350A1 (en) | 2024-03-13 |
| KR20240004937A (ko) | 2024-01-11 |
| BR112023022975A2 (pt) | 2024-01-23 |
| IL308258A (en) | 2024-01-01 |
| CO2023014734A2 (es) | 2024-02-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12162940B2 (en) | BMA031 antigen binding polypeptides | |
| TWI878330B (zh) | 特異性結合mage-a的抗原結合蛋白 | |
| TWI830761B (zh) | 針對cldn18.2和cd3之抗體構建體 | |
| CN107922495B (zh) | 结合egfrviii和cd3的双特异性抗体构建体 | |
| JP6526561B2 (ja) | インターロイキン−2融合タンパク質及びそれらの使用 | |
| TWI827570B (zh) | 雙特異性抗體產品之連續製造製程 | |
| JP2024164156A (ja) | Vista抗原結合性分子 | |
| US11859009B2 (en) | Antigen binding proteins specifically binding PRAME | |
| JP2022543387A (ja) | 修飾二特異性抗cd3抗体 | |
| EA039594B1 (ru) | Биспецифические конструкции антител к bcma и cd3, вовлекающие т-клетки | |
| TWI876227B (zh) | 多特異性抗體及其藥物用途 | |
| JP2023547661A (ja) | Cd3に結合するポリペプチド構築物 | |
| CN121358777A (zh) | 抗mageb2的抗原结合蛋白 | |
| CN117255805A (zh) | Bma031抗原结合多肽 | |
| HK40105268A (en) | Bma031 antigen binding polypeptides | |
| US20250034227A1 (en) | Antigen binding proteins against mageb2 | |
| HK40091509A (en) | Antigen binding proteins that specifically bind to mage-a | |
| EA043696B1 (ru) | Биспецифические конструкции антител к psma и cd3, вовлекающие т-клетки |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20240502 |
|
| RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20250206 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20250502 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20250620 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20260310 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20260603 |